All trading involves risk. Losses can exceed deposits.

CSL remains on top

CSL remains the global leader in biopharmaceutical therapies; its plasmas derived therapies continue to be the market leader in its field. 

All trading involves risk. Losses can exceed deposits.
ASX 200
Source: Bloomberg

Its bio range of vaccines and anti-venoms remain unrivalled and its operations in the key US and Europe markets continue to attract high level expertise and investment.

From a fundamental point of view, there are three key reasons CSL continues to be a stock of choice:

  1. EPS growth over the past six years has averaged 21%; the consensus estimates see CSL growing at a rate of 16% in FY15 and FY16.
  2. The company’s growth profile remains a core belief of management and therefore funding for organic growth comes from spending 6% of revenue in its research and development divisions. The results that are being produced from this division is highly encouraging, particularly the developments in the Immune Globulin subcutaneous liquids (IG), which is progressing well in the US and European markets.
  3. Scale and product innovation, coupled with very measured and conservative capital management we see as key drivers for CSL’s value going forward and remains a key reason why we like CSL’s strategy.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Find articles by analysts